港股创新药行情火热，恒生创新药ETF（520500）显著放量，单日成交额创历史新高

Group 1 - The Hong Kong innovative drug sector has shown strong performance recently, attracting significant southbound capital inflows, with a net inflow of 6.771 billion yuan from June 9 to June 13, making it the top sector for southbound funds [1] - The Hang Seng Innovative Drug ETF (520500) has seen a notable increase in trading activity, with a daily trading volume exceeding 600 million yuan as of June 16, significantly higher than the average daily trading volume of 140 million yuan from January 1 to March 31, 2025 [1] - The Hang Seng Innovative Drug ETF has experienced continuous net inflows for seven consecutive trading days since June 5, with fund shares and scale reaching 39.5 million shares and 650 million yuan, respectively, marking new highs since its establishment on December 16, 2024 [1] Group 2 - The Hang Seng Innovative Drug ETF (520500) is currently the only ETF tracking the Hang Seng Innovative Drug Index (HSIDI.HI) in the A-share market, supporting T+0 trading [1] - The index includes 40 Hong Kong-listed innovative drug companies with strong R&D capabilities and growth potential, reflecting the overall performance of the innovative drug sector [1] - The index has achieved a remarkable increase of 90.98% over the past year, serving as a valuable tool for investors to capitalize on the current innovative drug market trend [1] Group 3 - The recent recovery in the Hong Kong innovative drug sector is attributed to both technological innovations and favorable fundamental and policy support, which provide valuation support for the industry [1] - Several Chinese innovative drug companies have formed partnerships with state-owned pharmaceutical giants to expand into overseas markets, potentially accelerating their international growth [1] - A recent State Council meeting on June 13 discussed optimizing drug and consumable procurement measures, which may further promote high-quality development in the innovative drug industry [1]